Home › Encyclopedia › Ibutamoren: Research Status, Trials, and Identity
Approved

Ibutamoren: Research Status, Trials, and Identity

Molecular formulaC27H36N4O5S
Molecular weight528.7 g/mol
Registered trials8
PubChem CID178024

Many people searching for ibutamoren want to know whether it is an approved medicine. It is not: no FDA label exists for this compound, despite its presence in clinical research settings.

What ibutamoren is

Ibutamoren, also studied under the code MK-0677, is a small molecule with the chemical formula C27H36N4O5S and a molecular weight of about 528.7. It is identified in chemical databases under PubChem CID 178024. No FDA-approved drug label exists for ibutamoren, so no indications, mechanism summary, or brand name can be drawn from label data.

Trial footprint

Ibutamoren has been registered in 8 clinical trials. A completed Phase 2 trial examined an oral growth hormone drug for fibromyalgia. A Phase 2 trial looking at the compound's effect on lean body mass in people with advanced chronic kidney disease was withdrawn. A related compound, LUM-201, is the subject of an ongoing Phase 3 trial in children with growth hormone deficiency, recruiting participants.

FAQ

Is ibutamoren FDA-approved?
No. Ibutamoren does not have an FDA-approved label or indication. It remains a research compound studied in clinical trials rather than an approved medicine.
What is ibutamoren also known as?
Ibutamoren is also referred to by the research code MK-0677 in clinical trial records. Both names refer to the same compound, identified as PubChem CID 178024.
How many clinical trials have studied ibutamoren?
Ibutamoren has been registered in 8 clinical trials to date. These include studies in conditions such as fibromyalgia and chronic kidney disease, along with related compound research in growth hormone deficiency.
What conditions has ibutamoren been studied for?
Trial records show ibutamoren has been studied for fibromyalgia and for lean body mass changes in people with advanced chronic kidney disease. A related compound, LUM-201, is being studied for growth hormone deficiency in children. None of these uses are FDA-approved.
Is there safety data available for ibutamoren?
No FDA adverse event report data is currently available for ibutamoren in this dataset. Readers should rely on findings from registered clinical trials for safety information.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: ClinicalTrials.gov PubChem

Updated 2026-11-07